Comorbidities of COPD

International audienceBy 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality. Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco smoking is a common risk factor for many comorbidities, including coronary heart disease, heart failure and lung cancer. Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD, whereas others, such as systemic venous thromboembolism, anxiety, depression, osteoporosis, obesity, metabolic syndrome, diabetes, sleep disturbance and anaemia, have no evident physiopathological relationship with COPD. The common ground between most of these extrapulmonary manifestations is chronic systemic inflammation. All of these diseases potentiate the morbidity of COPD, leading to increased hospitalisations and healthcare costs. They can frequently cause death, independently of respiratory failure. Comorbidities make the management of COPD difficult and need to be evaluated and treated adequately. Extrapulmonary comorbidities are common in COPD and influence prognosis; we propose an exhaustive comorbidities revie

Comorbidities: assessment and treatment

COPD is an umbrella term that is associated with several systemic manifestation, lung involvement, and comorbidities [1, 2]. Currently, the description of comorbidity is complicated and has three different domains: “(1) the coexistence of one or more diseases with no other causation, (2) coexistence of diseases that share common risk factors and pathogenic pathways, (3) coexistence of diseases that are complicated by the interaction with the lung and systemic manifestation of COPD” [3]. In a very recent study, BODE Investigator Group suggested that COPD is interlinked with several comorbidities larger than non-COPD controls indicating common pathobiological process [4]. The importance of comorbidities is their impact on clinical outcomes of a patient life. COPD is a life-threatening and disabling disease and comorbidities cause additional impact revealing impairment in quality of life and increasing mortality [3]

Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review

COPD; Comorbidity; MortalityEPOC; comorbilidad; MortalidadMPOC; Comorbilitat; MortalitatThis study aimed to describe the prevalence of comorbidities associated with chronic obstructive pulmonary disease (COPD) and their relation with relevant outcomes. A systematic review based on the PRISMA methodology was performed from January 2020 until July 2021. The MEDLINE, Lilacs, and Scielo databases were searched to identify studies related to COPD and its comorbidities. Observational studies on the prevalence of comorbidities in COPD patients and costs with health estimates, reduced quality of life, and mortality were included. Studies that were restricted to one or more COPD pain assessments and only specific comorbidities such as osteoporosis, bronchitis, and asthma were excluded. The initial search identified 1,409 studies and after applying the inclusion and exclusion criteria, 20 studies were finally selected for analysis (comprising data from 447,459 COPD subjects). The most frequent COPD comorbidities were: hypertension (range, 17%-64.7%), coronary artery disease (19.9%-47.8%), diabetes (10.2%-45%), osteoarthritis (18%-43.8%), psychiatric conditions (12.1%-33%), and asthma (14.7%-32.5%). Several comorbidities had an impact on the frequency and severity of COPD exacerbations, quality of life, and mortality risk, in particular malignancies, coronary artery disease, chronic heart failure, and cardiac arrhythmias. Comorbidities, especially cardiovascular diseases and diabetes, are frequent in COPD patients, and some of them are associated with higher mortality.University of Bahi

Respiratory insufficiency related to copd accelerates systemic inflammation, under-nutrition, and angiogenesis in esophageal malignancies

A number of esophageal cancer patients suffer from respiratory insufficiency due to the coexistence of chronic obstructive pulmonary disease (COPD). Aim: To test the hypothesis that COPD-related systemic hypoxemia may result in accelerated inflammation, malnutrition, and angiogenesis in esophageal cancer patients. Methods: Serum levels of C-reactive protein (CRP), albumin, transferrin, interleukin-1, interleukin-6, interleukin-8, TNF- a, platelet-derived growth factor (PDGF-BB), and midkine and patient BMI and weight-loss rate were determined and compared with blood oxygenation status (pO2, SaO2) in 35 esophageal cancer patients and 42 controls. Results: The incidence of cachexia tended to be higher in patients with systemic hypoxemia (67% vs 40%, p = 0.169). Mean SaO2 level was also significantly decreased in cachectic patients (90.3 vs 93.3%, p = 0.026) and pO2 exhibited a similar trend (58.0 vs 63.4 mmHg, p = 0.120). Transferrin (234 vs 316 mg/dl, p = 0.005) and albumin (31.9 vs 37.1 mg/dl, p = 0.002) concentrations were reduced and CRP was elevated (129.9 vs 54.7 mg/l, p = 0.004) in hypoxemic patients and correlated with pO2 (r = 0.47, p = 0.016; r = 0.48, p = 0.012; r = –0.37, p = 0.064) and SaO2 (r = 0.52, p = 0.006; r = 0.53, p = 0.006; r = –0.40, p = 0.042). Interleukin-6 (9.97 vs 2.21 pg/ml, p = 0.005) and midkine (2101 vs 944 pg/ml, p < 0.001) were elevated and PDGF-BB was decreased (12.2 vs 17.3 pg x 10-6/PLT, p = 0.014) in hypoxemic compared with normoxemic patients. Interleukin-6 and midkine negatively correlated with pO2 (r = –0.44, p = 0.016; r = –0.42, p = 0.011) and SaO2 (r = –0.54, p = 0.003; r = –0.57, p < 0.0001) and PDGF-BB correlated positively (r = 0.53, p = 0.003; r = 0.44, p = 0.020). Interleukin-8 level was affected by pO2 (r = -0.55, p = 0.015) and SaO2 (r = –0.55, p = 0.018) only in hypoxemic patients. Conclusions: COPD-related systemic hypoxemia negatively affects the status of esophageal cancer patients by accelerating inflammation, under-nutrition, and angiogenesis.Многие больные раком пищевода страдают от респираторной недостаточности из-за развития хронического обструктивного легочного заболевания (COPD). Цель: Проверить гипотезу о возможной связи системной гипоксемии, ассоциированной с COPD, с усилением воспалительных процессов, истощением и ангиогенезом у больных раком пищевода. Методы: у 35 больных раком пищевода и 42 здоровых доноров определяли уровень CRP, альбумина, трансферина, интерлейкина-1, интерлейкина-6, интерлейкина-8, TNF-α, PDGF-BB и мидкина в сыворотке крови, показатели BMI и потери веса больных, а также показатели уровня оксигенации крови (pO2 , SaO2 ). Результаты: частота возникновения кахексии была выше у больных с системной гипоксемией (67 против 40%, p = 0,169). Средний уровень SaO2 был также значительно снижен у больных с кахексией (90,3 против 93,3%, p = 0,026), с той же тенденцией и для уровня pO2 (58,0 против 63,4 mmHg, p = 0,120). Концентрации трансферина (234 против 316 мг/дл, p = 0,005) и альбумина (31,9 против 37,1 мг/дл, p = 0,002) были снижены, CRP повышен (129,9 против 54,7 мг/л, p = 0,004) у гипоксемических пациентов, что кореллировало с показателями pO2 (r = 0,47, p = 0,016; r = 0,48, p = 0,012; r = –0,37, p = 0,064) и SaO2 (r = 0,52, p = 0,006; r = 0,53, p = 0,006; r = –0,40, p = 0,042). Уровень интерлейкина-6 (9,97 против 2,21 pg/ml, p = 0,005) и мидкина (2101 против 944 pg/ml, p < 0,001) был также повышен, а уровень PDGF-BB понижен (12,2 против 17,3 pg × 10-6/PLT, p = 0,014) у гипоксемических больных по сравнению с показателями при нормоксемии. Уровни интерлейкина-6 и мидкина негативно кореллировали с показателями pO2 (r = –0,44, p = 0,016; r = –0,42, p = 0,011) и SaO2 (r = –0,54, p = 0,003; r = –0,57, p < 0,0001) и позитивно — с PDGF-BB (r = 0,53, p = 0,003; r = 0,44, p = 0,020). На уровень интерлейкина-8 влияли pO2 (r = –0,55, p = 0,015) и SaO2 (r = –0,55, p = 0,018) только у больных с гипоксемией. Выводы: ассоциированная с COPD системная гипоксемия негативно влияет на состояние больных раком пищевода за счет ускорения воспалительных процессов, истощения и ангиогенез

Unraveling the Complex Interactions Among Lung Cancer, COPD, Cardiovascular Disease, and Pulmonary Fibrosis: Overlapping Risks, Converging Pathways, and Integrated Care Approaches

Background: The coexistence of lung cancer, chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), and pulmonary fibrosis poses significant challenges in clinical management due to shared risk factors, overlapping pathogenic mechanisms, and the complexity of co-managing multimorbid conditions. Smoking, environmental exposures, and genetic predispositions are critical shared risk factors, while common molecular mechanisms such as oxidative stress, chronic inflammation, and aberrant tissue remodeling contribute to the pathogenesis of these diseases. This review comprehensively examines the prevalence, shared mechanisms, and clinical implications of these comorbid conditions, emphasizing the importance of integrated management strategies to improve patient outcomes. We further highlight research gaps and propose future directions for personalized therapeutic approaches

Management of the COPD patient with comorbidities: an experts recommendation document

Background: Chronic obstructive pulmonary disease (COPD) is associated with multiple comorbidities, which impact negatively on patients and are often underdiagnosed, thus lacking a proper management due to the absence of clear guidelines. Purpose: To elaborate expert recommendations aimed to help healthcare professionals to provide the right care for treating COPD patients with comorbidities. Methods: A modified RAND-UCLA appropriateness method consisting of nominal groups to draw up consensus recommendations (6 Spanish experts) and 2-Delphi rounds to validate them (23 Spanish experts) was performed. Results: A panel of Spanish internal medicine experts reached consensus on 73 recommendations and 81 conclusions on the clinical consequences of the presence of comorbidities. In general, the experts reached consensus on the issues raised with regard to cardiovascular comorbidity and metabolic disorders. Consensus was reached on the use of selective serotonin reuptake inhibitors in cases of depression and the usefulness of referring patients with anxiety to respiratory rehabilitation programmes. The results also showed consensus on the usefulness of investigating the quality of sleep, the treatment of pain with opioids and the evaluation of osteoporosis by lateral chest radiography. Conclusion: This study provides conclusions and recommendations that are intended to improve the management of the complexity of patients with COPD and important comorbidities, usually excluded from clinical trials. Keywords: chronic obstructive pulmonary disease, COPD, comorbidities, modified RANDUCLA, Delphi techniqu

Stratification of Outcomes After Transcatheter Aortic Valve Replacement According to Surgical Inoperability for Technical Versus Clinical Reasons

ObjectivesThe goal of this study was to examine the impact of reasons for surgical inoperability on outcomes in patients undergoing transcatheter aortic valve replacement (TAVR).BackgroundPatients with severe aortic stenosis may be deemed inoperable due to technical or clinical reasons. The relative impact of each designation on early and late outcomes after TAVR is unclear.MethodsPatients were studied from the inoperable arm (cohort B) of the randomized PARTNER (Placement of Aortic Transcatheter Valve) trial and the nonrandomized continued access registry. Patients were classified according to whether they were classified as technically inoperable (TI) or clinically inoperable (CLI). Reasons for TI included porcelain aorta, previous mediastinal radiation, chest wall deformity, and potential for injury to previous bypass graft on sternal re-entry. Reasons for CLI were systemic factors that were deemed to make survival unlikely.ResultsOf the 369 patients, 23.0% were considered inoperable for technical reasons alone; the remaining were judged to be CLI. For TI, the most common cause was a porcelain aorta (42%); for CLI, it was multiple comorbidities (48%) and frailty (31%). Quality of life and 2-year mortality were significantly better among TI patients compared with CLI patients (mortality 23.3% vs. 43.8%; p < 0.001). Nonetheless, TAVR led to substantial survival benefits compared with standard therapy in both inoperable cohorts.ConclusionsPatients undergoing TAVR based solely on TI have better survival and quality of life improvements than those who are inoperable due to clinical comorbidities. Both TI and CLI TAVR have significant survival benefit in the context of standard therapy. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894

A case of tracheobronchial amyloidosis presenting with acute myeloid leukemia

Localized tracheobronchial amyloidosis (TBA) is a rare form of pulmonary amyloidosis that is characterized by amyloidosis accumulation in the trachea and main bronchus submucosa. TBA is usually localized in the lung and is not associated with systemic amyloidosis. Although patients may be asymptomatic at first, they may develop dyspnea, recurrent cough, and hemoptysis attacks as the lesions narrow the tracheobronchial tree. Histochemical examination of biopsies taken with flexible bronchoscopy after thorax CT findings is usually used to make the diagnosis. There has never been a case reported in which TBA and acute myeloid leukemia (AML) coexisted. We report the first case of TBA in a patient diagnosed with AML